SPOTLIGHT: Novartis touts cancer data


Novartis has released positive data for RAD001 in advance of ASCO. According to interim data the therapy extended time without tumor growth from 1.9 months to 4 months and reduced the risk of progression by 70 percent. Release | Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.